中文别名:
替沃扎尼;N-[2-氯-4-[(6,7-二甲氧基-4-喹啉基)氧基]苯基]-N'-(5-甲基-3-异恶唑基)脲;VEGFR1/2/3抑制剂(TIVOZANIB);N-[2-氯-4-[(6,7-二甲氧基-4-喹啉基)氧基]苯基]-N'-(5-甲基-3-异恶唑基)脲;EPERTINIB HCL, S-222611 HYDROCHLORIDE, S-222611 HCL;化合物TIVOZANIB;替沃扎尼原料优势供应;N-[2-氯-4-(6,7-二甲氧基喹啉-4-基氧)苯基]-N′-(5-甲基异唑-3-基)脲
英文别名:
AV951
(KRN951, Tivozanib) (stopped use since the patent issue);AV-951; KRN951; AV 951;AV951;CS-8;Tivozanib, AV951,N-[2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)urea;AV951;AV-951;Tivozanib;N-[2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)urea